Latest news
PepGen Maintained at Buy as Analyst Cites Encouraging DM1 Safety/Efficacy Profile and Keeps $20 Price Target - TipRanksTipRanks · Fri, 07 Aug 2026 10:33:21 GMTH.C. Wainwright Maintains PepGen(PEPG.US) With Buy Rating, Maintains Target Price $20 - MoomooMoomoo · Fri, 07 Aug 2026 10:31:00 GMTPepgen Inc. (PGN) 2026 Q2 10-Q Report: Financials, Risks, and Forward-Looking Statements Overview - MinichartMinichart · Thu, 06 Aug 2026 23:51:00 GMTPepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - BioSpaceBioSpace · Thu, 06 Aug 2026 12:39:19 GMTPepGen: PGN-EDODM1 Multisystem Efficacy Potential Supports Buy Rating with Unchanged $20 Price Target - TipRanksTipRanks · Fri, 31 Jul 2026 18:20:26 GMT